Patents by Inventor Peter Knox

Peter Knox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220354117
    Abstract: The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (III) as defined herein for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection.
    Type: Application
    Filed: September 10, 2019
    Publication date: November 10, 2022
    Inventors: Peter John Roy, Sean Harrington, Andrew Burns, Jacob Edward Pyche, Genna M. Luciani, Jessica Knox, Mark Lautens, Ken Loon Choo
  • Publication number: 20220360921
    Abstract: The present application discloses systems and methods for determining one or more configuration settings for a first hearing prosthesis based on configuration data associated with a second hearing prosthesis. In some embodiments, determining the one or more configuration settings for the first hearing prosthesis may include determining an acoustic operating range associated with the first hearing prosthesis based on whether a configured gain at one or more frequencies for the second hearing prosthesis meets or exceeds a target gain at the one or more frequencies. Some embodiments may also include storing the determined configuration settings in a tangible computer readable memory associated with the first hearing prosthesis.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 10, 2022
    Inventor: Peter Knox
  • Publication number: 20220226454
    Abstract: Vaccines for Porphyromonas gingivalis are described. Also provided are methods of treating or preventing a disorder or disease by administering the vaccine.
    Type: Application
    Filed: January 10, 2022
    Publication date: July 21, 2022
    Inventors: Peter L. Nara, Jan Stanislaw Potempa, John Knox Tobin, Gregory John Tobin
  • Patent number: 9457106
    Abstract: The invention provides a method of treating a tumor or other lesion comprising introducing a solution comprising one or more radioactive isotopes directly into said tumor or other lesion in a mammal to effect in situ precipitation of a radioactive precipitate in the tumor or other lesion.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: October 4, 2016
    Inventor: Peter Knox
  • Publication number: 20140134104
    Abstract: The invention provides a method of treating a tumor or other lesion comprising introducing a solution comprising one or more radioactive isotopes directly into said tumour or other lesion in a mammal to effect in situ precipitation of a radioactive precipitate in the tumour or other lesion.
    Type: Application
    Filed: April 18, 2012
    Publication date: May 15, 2014
    Applicant: DSPI LTD.
    Inventor: Peter Knox
  • Patent number: 8372654
    Abstract: The invention is concerned with Nuclear Magnetic Resonance (NMR) spectroscopy and Magnetic Resonance Imaging (MRI), particularly NMR spectroscopy. It provides hyperpolarization methods offering enhanced sensitivity of detection over conventional NMR for studying the fate of a test compound in a biological system. The methods are particularly suitable for studying metabolism and toxicity of drugs. The resulting NMR sensitivity increase is advantageous in two key aspects of NMR detection: test compounds can be detected at lower concentrations and substantial time saving can be achieved in cases where extensive averaging is conventionally employed to increase the signal to noise ratio of the corresponding NMR spectra. The methods can be used for studios that were not practical or not possible using conventional NMR.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: February 12, 2013
    Assignee: GE Healthcare Limited
    Inventors: Neil Cook, Albie Santos, Nigel Bosworth, Jan Wolber, Mike Looker, Peter Knox, Jan Jenrik Ardenkjaer-Larsen, Klaes Golman
  • Publication number: 20120091008
    Abstract: A fluid sampling element is adapted to receive a fluid sample, but also includes a pH sensor element adapted to measure pH of the fluid sample and a reference sensor element. The pH sensor element and the reference sensor element are adapted to generate a potential difference between each other based on the pH of the fluid sample. The pH of the fluid sample can be measured and the fluid sampling element can then be readily disposed of.
    Type: Application
    Filed: May 4, 2010
    Publication date: April 19, 2012
    Applicant: MEDERMICA LIMITED
    Inventors: Beinn V. O. Muir, Eleni Bitziou, Danny O'Hare, Peter Knox
  • Patent number: 7501236
    Abstract: An in vitro assay method which comprises the use of an assay reagent containing at least one NMR active nucleus, and hyperpolarising at least one NMR active nucleus of the assay reagent; and analysing the assay reagent and/or the assay by NMR spectroscopy and/or NMR imaging. The assay reagent may contain an artificially high concentration of an NMR active nucleus.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: March 10, 2009
    Assignee: GE Healthcare Limited
    Inventors: Peter Knox, Neil Cook, Klaes Golman, Haukur Johannesson, Oksar Axelsson, Jan Henrik Ardenkjaer-Larsen
  • Publication number: 20070043327
    Abstract: This invention concerns drug delivery by way of mesh sleeves for use with devices adapted for insertion into the vagina, rectum, nasal or buccal cavity. The resulting apparatus exploit the highly vascularised nature of the tissue of bodily cavities such as the vagina, nose, rectum and mouth to deliver pharmaceutical agents to localised areas and/or into underlying tissues.
    Type: Application
    Filed: March 26, 2004
    Publication date: February 22, 2007
    Inventor: Peter Knox
  • Publication number: 20060292075
    Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Application
    Filed: April 24, 2006
    Publication date: December 28, 2006
    Inventors: Anthony Storey, Marivi Mendizabal, Susan Champion, Alex Gibson, Benedicte Guilbert, Ian Wilson, Peter Knox
  • Publication number: 20060135501
    Abstract: This invention relates to compounds of formula (I) and (II) that are useful in treating vascular endothelial growth factor (VEGF)-mediated disorders, particularly endometriosis and acute macular degenerative disorder. The invention also relates to a topical system for the treatment of acute macular degenerative disorder comprising a VEGF inhibitor.
    Type: Application
    Filed: December 24, 2003
    Publication date: June 22, 2006
    Inventors: Peter Knox, Michele O'Sullivan, Heike Lentfer
  • Patent number: 7049289
    Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: May 23, 2006
    Assignee: Amersham PLC
    Inventors: Anthony Eamon Storey, Marivi Mendizabal, Susan Champion, Alex Gibson, Benedicte Guilbert, Ian Andrew Wilson, Peter Knox
  • Patent number: 6897209
    Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m-A-NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: May 24, 2005
    Assignee: GE Healthcare Limited
    Inventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
  • Publication number: 20050049231
    Abstract: The invention relates to a method for the treatment of an oestrogen-dependent proliferative disorder of the uterus such as endometriosis and uterine fibroids in a patient, by administering an aromatase inhibitor to the patient intravaginally. This achieves high local levels of aromatase inhibitor Locally, and therefore avoids some of the adverse reactions that are observed when aromatase inhibitors are delivered orally. Further, intravaginal delivery allows inhibition of the local lesional production without significantly affecting the circulating levels which have been produced by the ovaries. This results in minimal side-effects and will allow for longer term treatment than current therapies.
    Type: Application
    Filed: August 16, 2002
    Publication date: March 3, 2005
    Inventors: Peter Knox, Helen Pappa
  • Publication number: 20050032680
    Abstract: The invention relates to a method for the treatment of vulvar vestibulitis, by the topical application to an affected tissue of a therapeutically-effective amount of an agent that prevents or reduces the activation of T-lymphocyte cells, such as tacrolimus, everolimus, sirolimus or cyclosporin.
    Type: Application
    Filed: October 31, 2002
    Publication date: February 10, 2005
    Inventor: Peter Knox
  • Patent number: 6758840
    Abstract: The invention relates to drug delivery devices for insertion into the vagina, rectum or nasal cavity comprising a body, a layer of fluid-impermeable material on at least part of said body and one or more pharmaceutical agents disposed on the surface of the material remote from said body, wherein said body comprises absorbent material. The devices exploit the highly vascularised nature of the vaginal, nasal and rectal mucosal tissue to deliver pharmaceutical agents to localised areas and/or into underlying tissues.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: July 6, 2004
    Assignee: Metris Therapeutics Limited
    Inventor: Peter Knox
  • Publication number: 20040076580
    Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m—A—NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Application
    Filed: August 22, 2003
    Publication date: April 22, 2004
    Applicant: AMERSHAM PLC
    Inventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
  • Publication number: 20040039281
    Abstract: The invention is concerned with Nuclear Magnetic Resonance (NMR) spectroscopy and Magnetic Resonance Imaging (MRI), particularly NMR spectroscopy. It provides hyperpolarisation methods offering enhanced sensitivity of detection over conventional NMR for studying the fate of a test compound in a biological system. The methods are particularly suitable for studying metabolism and toxicity of drugs. The resulting NMR sensitivity increase is advantageous in two key aspects of NMR detection: test compounds can be detected at lower concentrations and substantial time saving can be achieved in cases where extensive averaging is conventionaly employed to increase the signal to noise ratio of the corresponding NMR spectra. The methods can be used for studios that were not practical or not possible using conventional NMR.
    Type: Application
    Filed: July 17, 2003
    Publication date: February 26, 2004
    Inventors: Neil Cook, Albie Santos, Nigel Bosworth, Jan Wolber, Mike Looker, Peter Knox, Jan Jenrik Ardenkjaer-Larsen, Klaes Golman
  • Patent number: 6653299
    Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula —(Y)m—A—NHR, can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Grant
    Filed: October 4, 1999
    Date of Patent: November 25, 2003
    Assignee: Nycomed Amersham PLC
    Inventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
  • Patent number: 6375926
    Abstract: A human leucocyte elastase (HLE) inhibitor labelled with a detector moiety where the inhibitor is synthetic and has a molecular weight of less than 2000, is useful for the diagnostic imaging of sites of inflammation of infection in vivo, for labelling leucocytes in vitro, or for radiotherapy of rthritis. The HLE inhibitor is preferably a &bgr;-lactam or an azetidinone.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: April 23, 2002
    Assignee: Amersham International PLC
    Inventors: Karen Jane Barnes, Gary Robert Bower, Alan Michael Forster, Peter Knox, Marivi Mendizabal, Anthony Eamon Storey